期刊文献+

羟氯喹对CpG-ODN诱导浆细胞样树突状细胞活化影响的初步研究 被引量:3

Impact of hydroxychloroquine on pl CpG-ODN-induced asmacytoid dendritic cells activation
下载PDF
导出
摘要 目的体外探讨羟氯喹(HCQ)对CpG—ODN诱导pDCs活化的影响。方法产房收集脐带血250-300ml.密度梯度离心得脐带血单核细胞,BDCA-4磁珠分选得前体pDCs细胞,前体pDCs分为3组(IL-3,IL-3+CpG,IL-3+CpG+HCQ)培养3d.流式细胞术测pDCs表面BDCA-2、CD86、CD32表达,ELISA检测上清细胞因子IFN-α水平。结果①IL-3+CpG组BDCA-2表达水平和荧光强度均显著低于IL-3组(P〈0.05);CD86和CD32表达水平、荧光强度和培养上清IFN—α浓度显著高于IL-3组(P〈0.05)。②IL-3+CpG+HCQ组CD32表达水平和荧光强度均显著低于IL-3+CpG组(P〈0.05);培养上清IFN—α浓度显著低于IL-3+CpG组(P〈0.05)。结论CpG—ODN可以活化pDCs,活化的pDCs高表达CD86、CD32,低表达BDCA-2;HCQ抑制CD32表达.抑制CpG—ODN诱导的DDCs活化.减少IFN-α的分泌。 To investigate the impact of hydroxychloroquine (HCQ) on plasmacytoid dendritic cells activation induced by CpG-ODN in vitro, cord blood (250-300 ml) was collected from delivery room. Density gradient centrifugation was used to get the cord blood monocytes and BDCA-4 beads sorting was used to obtain the precursor pDCs. Precursor pDCs was co-cuhured with IL-3, IL-3 plus CpG-ODN2216, and IL-3 plus CpG- ODN2216+HCQ, respectively for 3 days. Then flow cytometry was used to measure the pDCs surface expression of BDCA-2, CD86 and CD32; while ELISA was employed to detect the concentration of IFN-α in the supernatants. We found that CpG-ODN2216 activated pDCs demonstrated higher expressions of CD86 and CD32, more IFN-α production, but lower expression of BDCA-2 in vitro (P 〈 0.05). And HCQ could significantly down-regulate the CD32 expression, CD32 MFI level, and IFN-α level in the supernatants (P〈 0.05). In conclusion, HCQ may inhibit pDCs activation and IFN-α secretion induced by CpG-ODN2216 via reducing CD32 expression on pDCs.
出处 《免疫学杂志》 CAS CSCD 北大核心 2013年第1期14-18,共5页 Immunological Journal
基金 国家自然科学基金(81072462) 安徽省高校自然科学重点项目(KJ2010A188)
关键词 浆细胞样树突状细胞 羟氯喹 干扰素-Α Plasmaeytoid dendritic cells Hydroxychloroquine Interferon-alpha
  • 相关文献

参考文献14

  • 1Robak E, Sysa Jedrzejowska A, Robak T, et al. Peripheral blood lymphocyte apoptosis and circulating dendritic cells in patients with systemic lupus erythematosus correlationwith immunological status and disease-related symptom[J]. Clin Rheumatol, 2006, 25(2): 225-233.
  • 2Zhuang H, Narain S, Sobel E, et al. Association of anti- nucleoprotein autoantibodies with upregulation of Type I interferon-inducible gene transcripts and dendritic cell maturation in systemic lupus erythematosus[J]. Clin Immunol, 2005, 117(3): 238-250.
  • 3Means TK, Latz E, Hayashi F, et al. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9[J}. J Clin Invest, 2005, 115(2): 407-417.
  • 4Santer DM, Wiedeman AE, Teal TH, et al. Plasmacytoid dendritic cells and Clq differentially regulate inflammatory gene induction by lupus immune complexes[J]. J Immunol, 2012, 188(2): 902-915.
  • 5Hagberg N, Berggren O, Leonard D, et al. IFN--ct production by plasmacytoid dendritic cells stimulated with RNA- containing immune complexes is promoted by NK cells via MIP-1 b and LFA-I[J]. J Immunol, 2011, 186(9): 5085- 5094.
  • 6Wu P, Wu J, Liu S, et al. TLR9/I'LR7-triggered downregulation of BDCA2 expression on human plasmacytoid dendritic cells from healthy individuals and lupus patients[J]. Clin Immunol, 2008, 129(1): 40--48.
  • 7Fujii S, Liu K, Smith C, et al. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation[J]. J Exp Med, 2004, 199(12): 1607-1618.
  • 8Nie YJ,Mok MY, Chan GC, et al. Phenotypic and functional abnormalities of bone marrow--derived dendritic cells insystemic lupus erythematosus[J]. Arthritis Res Ther, 2010, 12(3): R91.
  • 9Rnnblom L, Eloranta ML, Alm G. The type I interferon system in systemic lupus erythematosus[J]. Arthritis Rheum, 2006, 54(2): 408-,420.
  • 10LSvgren T, Eloranta ML, Bive U. Induction of interferon- alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG[J]. Arthritis Rheum, 2004, 50(6): 1861-1872.

同被引文献31

  • 1Wu P, Wu J, Liu S, et al. TLR9/TLR7-triggered downregulation of BDCA2 expression on human plasmacytoid dendritic cells from healthy individuals and lupus patients[J]. Clin Immunol, 2008, 129(1): 40-48.
  • 2Macarlane E, Manzel L. Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds [J]. J Immunol, 1998, 160(3): 1122-1131.
  • 3Skinner Adams S, Davis TM, Manning LS, et al. The efficacy of benzimidazoles drug against plasmodium falciparum in vitro[J]. TransR Soc Trop Med Hyg, 1997, 91(5): 580 - 584.
  • 4Lood C, Gullstrand B, Truedsson L, et al. Clq inhibitsimmune complex-induced interferon-c production in plasmacytoid dendritic cells[J]. Arthritis Rheum, 2009, 60(10): 3081-3090.
  • 5Shinjo SK, Bonf6 E, Wojdyla D, et al. Antimalarials may have a time-dependent effect in lupus survival: Data from the multinational latin American inception GLADEL cohort[J]. Arthritis Rheum, 2010, 62(3): 855-862.
  • 6Namazi MR. The potential negative impact of proton pump inhibitors on the immunopharmacologic effects of chloroquine and hydroxychloroquine[J]. Lupus, 2009, 18(2): 104-105.
  • 7Kuznik A, Bencina M, Svajger U, et al. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines[J]. J Immunol, 2011, 186(8): 4794-804.
  • 8Lowe G, Henderson CL, Grau RH, et al. A systematic review of drug-induced subacute cutaneous lupus erythematosus[J]. Br J Dermatol, 2011, 164(3): 465-472.
  • 9Almebayadh M, Regnier Rosencher E, Carlotti A, et al. Subacute cutaneous lupus erythematosus induced and exacerbated by proton pump inhibitors [J]. Dermatology, 2013, 226(2): 119-123.
  • 10Kochar DK, Saini GA, Kochar SK, et al. A double blind, randomised placebo controlled trial of rifampicin with omeprazole in the treatment of human cutaneous leishmaniasis[J]. J Vector Borne Dis, 2006, 43(4): 161-167.

引证文献3

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部